A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Inclusion criteria

• Postmenopausal female participants
• Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)

Exclusion criteria

• Have an unstable disease or a disease constituting a risk when taking the study intervention.
• Have significant renal insufficiency
• Have an important gastro-esophageal reflux disease, pyloric stenosis, gastroparesis or a history of gastric bypass surgery.
• Have a history or presence of chronic or idiopathic acute pancreatitis.
• Have a history of severe clinically significant multiple or severe drug allergies.
• Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
• Have had any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix that have been resected with no evidence of metastatic disease for 3 years
• Have any form of diabetes mellitus other than type 2
• Have type 2 diabetes with HbA1c greater than or equal to 10% at screening
• Have received an oral or transdermal patch hormone replacement therapy (HRT) within the last 1 month prior to screening or depot injectable HRT within the last 6 months
• Have received any investigational drug within the last month or 5 half-lives of this drug, whichever is longer, prior to screening. If the half-life of the previous investigational drug is unknown, the washout period should be at least 3 months before screening
• Show evidence of HIV infection or positive HIV antibodies
• Have evidence of, or test positive for, anti-hepatitis C virus antibody unless a confirmatory test for hepatitis C virus RNA is negative
• Test positive for hepatitis B surface antigen. In case a hepatitis B virus DNA test was also performed recently and is positive, the participant should be excluded independently of the hepatitis B surface antigen test result. The hepatitis B core antibody test is not used to assess eligibility
• Have acute or chronic hepatitis, or signs and symptoms of any other liver disease, or with significant abnormalities in laboratory liver tests
• Have a fasting triglyceride level greater than 500 mg/dL at screening
• Used any nicotine product including tobacco or nicotine replacement products within 1 month prior to screening or a positive cotinine test at screening. Are unable or unwilling to refrain from using such products during the study
• Have donated at least 450 mL of blood within 8 weeks before screening or intend to donate blood during the study